［1］Levesque E,Belanger AS,Harvey M,et al.Refining the UGT1A haplotype associated with irinotecan-induced hematological toxicity in metastatic colorectal cancer patients treated with 5-fluorouracil/irinotecan-based regimens［J］.J Pharmacol Exp Therapeutics,2013,345(1):95-101.
[2] Nakamura Y，Soda H，Oka M，et al．Randomized phase II trial of irinotecan with paclitaxel or gemcitabine for non-small cell lung cancer:Association of UGT1A1*6 and UGT1A1*27 with severe neutropenia［J］．J Thorac Oncol，2011，6(1):121－127．
[3]Innocenti F，Undevia SD，Iyer L，et al．Genetic variants in the UDP-glucuronosyltransferase 1A1 gene predict the risk of severe neutropenia of irinotecan［J］．J Clin Oncol，2004，22（8）：1382－1388．
[4]Massacesi C，Terrazzino S，Marcucci F，et al．Uridine diphosphate glucuronosyl transferase 1A1 promoter polymorphism predicts the risk of gastrointestinal toxicity and fatigue induced by irinotecan-based chemotherapy［J］.Cancer，2006，106（5）：1007－1016．
[5]Liu XL,Yang MD,Gao J.Relationship between UGT1A1 gene polymorphisms and toxicity of irinotecan［J］.Chin Remedies & Clin,2013,13(11):1402-1404.
[6]Shulman K，Cohen I，Barnett-Griness O，et al．Clinical implications of UGT1A1*28 genotype testing in colorectal cancer patients［J］．Cancer，2011,117(14):3156-3162．
[7]Pan ZY,Jiang ZS,Ba Y,et al.Effect of herbs on preventing diarrhea caused by irinotecan and its correlation with gene polymorphism of UGT1A1*28［J］.Chin J Clin Oncol,2013,40(23):1441-1444.［潘战宇，姜战胜， 巴一，等.UGT1A1*28基因多态性与中药预防伊立替康腹泻效果的关系［J］.中国肿瘤临床，2013,40(23):1441-1444.］
[8]Ando Y，Saka H，Ando M，et al．Polymoephisms of UDP glucuronosyltransferase gene and irinotecan toxicity：A phannacogentic analysis［J］．Cancer Res，2000，60(24)：6921-6926．
[9]Hirose K，Kozu C，Yamashita K，et al.Correlation between plasma concentration ratios of SN-38 glucuronide and SN-38 and neutropenia induction in patients with colorectal cancer and wild-type UGT1A1 gene［J］.Oncol Lett,2012,3(3):694-698.
[10]Zhang A，Xing Q，Qin S，et al．Intra-ethnic differences in genetic variants of the UGT-glucuronosyltransferase 1A1 gene in Chinese populations［J］．Pharmacogenomics J，2007，7（5）：333-338．
[11] Ma D,Zhang XC,Yang DY,et al．Association of UGT1A1*28 polymorphism with toxicity and efficacy of innotecan in Chinese patients［J］.J Sun Yat-sen University(Medical Sciences),2011,32(4):495-499.［马冬，张绪超，杨冬阳，等．中国人UGT1A1*28 的基因多态性以及与伊立替康毒性和疗效的关系［J］．中山大学学报（医学科学版），2011，32（4）：495-499．］
[12]Kaniwa N，Kurose K，Jinno H，et al．Racial variability in haplotype frequencies of UGT1A1 and glucuronidation activity of a novel single nucleotide polymorphism 686C＞T （P229L）found in an African-American［J］．Drug Metab Dispos，2005，33（3）：458-465．
[13] Wang Yan,Ge Feijiao,Lin Li,et al.Correlation between UGT1A1 gene polymorphisms and toxicity and efficacy in patients with metastatic colorectal cancer treated with irinotecan based chemotherapy［J］.Chin Clin Oncol,2012,17(11):961-966.
[14]Lv YL,Liu W,Du YJ,et al.Clinical study of the correlation between UGT1A1 polymorphism and safety and efficacy of irinotecan［J］.Chin J Clin Oncol,2012，39（20）：1542-1545．［吕亚蕾，刘巍，杜玉娟，等．UGT1A1基因多态性以及与伊立替康安全性和有效性的临床研究［J］.中国肿瘤临床，2012，39（20）：1542-1545．］
[15]Yuan Zhenyan,Yan Han,Li Qin,et al.Association between the polymorphisms of UGT1A1*28 genotype and irinotecan-related toxicity：A Meta-analysis［J］.Chin J Clinicians(Electronic Edition)，2013，7（19）：8791-8798.［原振龑,闫涵，李琴，等.UGT1A1*28基因多态性与伊立替康相关不良反应Meta分析［J］.中华临床医师杂志，2013，7（19）：8791-8798.］
[16]Hu ZY，Yu Q，Zhao YS，et al．Dose - dependent association between UGT1A1* 28 polymorphism and irinotecan-induced diarrhoea:A Meta-analysis［J］．Eur J Cancer，2010，46(10):1856-1865．
[17]Onoue M，Terada T，Kobayashi M，et al.UGT1A1*6 polymorphismis most predictive of severe neutropenia induced by irinotecan in Japanese cancer patients［J］.Int J Clin Oncol，2009，14(2):136-142.
[18] Takahara N，Nakai Y，Isayama H,et al.Uridine diphosphate glucuronosyl transferase 1 family polypeptide A1 gene (UGT1A1) polymorphisms are associated with toxicity and efficacy in irinotecan monotherapy for refractory pancreatic cancer［J］.Cancer Chemotherapy and Pharmacol,2013,71(1):85-92.
[19]Teh LK，Hashim H，Zakaria ZA，et al．Polymorphisms of UGT1A1*6，UGT1A1* 27 ＆ UGT1A1* 28 in three major ethnic groups from Malaysia［J］．Indian J Med Res，2012，136(2):249-259.
[20]Zhang Junxiao,Wang Chenliang,Huang Yingmai，et al.Relationship between UGT1A1 gene polymorphisms and toxicity/efficacy of irinotecan-based chemotherapy in metastatic colorectal cancer［J］.Chin J Pathophysiol，2012,28（5）：823-828.［张军孝，王晨亮，黄英迈，等.UGT1A1 基因多态性与转移性结直肠癌伊立替康化疗毒性及疗效的关系［J］.中国病理生理杂志，2012，28(5):823-828.］
[21]Sunakawa Y，Ichikawa W，Fujita K，et al．UGT1A1*1/*28 and*1/*6 genotypes have no effects on the efficacy and toxicity of FOLFIRI in Japanese patients with advanced colorectal cancer［J］．Cancer Chemother Pharmacol，2011，68(2):279－284．
[22]Zhao Rongrong,Niu Zuoxing.Association of UGT1A1*28 polymorphism with the efficacy and toxicity of irinotecan chemotherapy［J］.Chin J Cancer Prev Treat,2013,20(9):717-720.
[23] Zhang Yong,Su Dan,Zhang Tingting，et al．The relationship between UGT1A1 gene polymorphisms and the toxicity and efficacy of irinotecan-based chemotherapy in advanced colorectal cancer［J］.Chin J Drug Application and Monitoring,2014,5:263-266.
[24]Cecchin E，Innocenti F，D'Andrea M，et al．Predictive role of the UGT1A1，UGT1A7，and UGT1A9 genetic variants and their haplotypes on the outcome of metastatic colorectal cancer patients treated with fluorouracil，leucovorin，and irinotecan［J］．J Clin Oncol，2009，27(15):2457－2465．
[25]Gagne JF，Montminy V，Belanger P，et al．Common human UGT1A polymorphisms and the altered metabolism of irinotecan active metabolite 7-ethyl-10-hydroxycamptothecin (SN-38) ［J］．Mol Pharmacol，2002，62(3):608－617.